Objective A recently discovered myokine, irisin, may have an important role in energy metabolism. This study aimed to evaluate the relationship between this hormone and the lipid profile of Metabolic Syndrome (MetS) patients following a hypocaloric diet.
Introduction
Irisin is a recently discovered myokine, proteolytically processed from the product of the fibronectin type 3-domain containing protein 5 (FNDC5) gene 1 , with a possible role in the regulation of energy metabolism. As a novel hormone, several studies are being carried out in order to understand its different functions. Irisin has been reported to be expressed in skeletal muscle and to participate in white fat browning 2 . It might also have an antidiabetic role by improving glucose homeostasis 3 . Also, an inverse association with liver fat content has been described 4 and as irisin increases with exercise 2,5 , a relation with follistatin, a peptide that regulates muscle growth, has been also shown 6 . Furthermore, an association between irisin and the lipid profile has also been described. However, results from the different studies on the target do not reach an agreement. This situation may be due to the fact that the studies have been carried out in different populations under different conditions.
In this context, the increasing prevalence of metabolic syndrome (MetS) is considered a major concern for public health authorities; they regard MetS as an important burden with relevant adverse features and complications 7 . Among the different metabolic abnormalities comprising the MetS, excessive adiposity and dyslipidemia have been considered of major clinical relevance due to the well-established relations with diabetes and coronary events 8, 9 . Hence, much scientific effort is currently being directed to detect, treat and prevent MetS manifestations, focusing on decreasing body weight 10, 11 and lowering the associated risks of lipid metabolism abnormalities 12 . In light of this, the present study aimed to investigate the possible relationships of this novel myokine (irisin) with the lipid profile of patients suffering MetS under a caloricrestricted programme: the RESMENA-S (Metabolic Syndrome Reduction in NavarraSpain) project (www.clinicaltrials.gov; NCT01087086).
Materials and methods

Study design
This research reports the findings of a sub-analysis of the first 8-weeks of a nutritional intervention within the RESMENA-S project, which has been previously described in detail 13, 14 . Briefly, the study was a randomised, controlled trial that compared the effects of two hypocaloric (-30% of the studied requirements) dietary strategies, control and RESMENA diets, on MetS, described elsewhere 14, 15 . The control diet was based on the American Heart Association guidelines 16 , including 3-5 meals per day, a macronutrient distribution of 55% total caloric value (TCV) from carbohydrates, 15% from proteins and 30% from lipids, as well as a healthy fatty acid (FA) profile and a cholesterol consumption below 300 mg/day. The RESMENA diet was characterised by a higher meal frequency, consisting of seven meals per day and having a different macronutrient distribution which was as follows: 40% TCV from carbohydrates, 30% from proteins and 30% from lipids. 
Anthropometric and biochemical measurements
Anthropometric and body composition measurements were taken in fasting conditions as was previously described . Body weight was assessed to the nearest 0·1 kg using bio-impedance (TANITA SC-330; Tanita Corporation) equipment. BMI was calculated as the body weight divided by height squared (kg/m ). Waist and hip circumferences were measured using a commercial measuring tape and following validated protocols .
Total body fat mass and android fat mass were determined using dual-energy X-ray absorptiometry (Lunar iDXAe, software version 6·0; GE Healthcare). Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were assessed using a digital monitor (Medisana AG, MTC) according to the World Health Organization criteria.
Serum total cholesterol (TC), 1024 ng/mL and exhibited an inter and intra-assay coefficient of variation of 6-10%.
The samples were kept at -80ºC and were analysed during the month following the end of the study.
Statistical analyses
This study is a sub-analysis of data obtained as a part of the RESMENA-S study.
Statistical tests were performed using the SPSS 15·0 software for Windows (SPSS Ibérica, Madrid, Spain). Mean values and standard deviations of the measured variables were reported. Differences were considered statistically significant at p < 0·050.
Based upon previous studies , the required sample size (forty per group) in the randomised controlled trial was calculated to detect a difference of 4·3 cm, with a variation of ± 6·8 cm between the groups in the reduction of waist circumference with a p < 0·05 and a power of 80 %. The estimated dropout rate was 25%, and the initial number of recruited subjects was 109. The intervention trial started with ninety-three subjects presenting MetS and ended with forty per group (figure 1). 21, 22 Differences between the beginning and the end of the intervention were analysed in 
Results
Anthropometric and biochemical markers
Both dietary strategies proved to be effective in improving anthropometric and biochemical markers (table 1) . Overall, control and RESMENA groups reduced body weight, BMI, waist circumference, waist to hip ratio (WHR) as well as total and android fat mass percentages with a statistically significant p value < 0·001. Both dietary strategies also resulted in a decline in the SBP and DBP measurements. As for biochemical markers, Apo B, TG and glucose levels were significantly diminished in both dietary groups. TC, HDL-c and LDL-c reductions only reached statistical significance in the control subjects, although they decreased in both dietary groups.
Indeed, no statistically significant differences between control and RESMENA dietary strategies were observed in any of the anthropometric and biochemical variables (table   1) . Therefore, both dietary groups were merged for further analyses.
Regarding plasma irisin levels, they presented a statistically significant reduction in both dietary groups (-87·3 ± 114·2 ng/mL control, -57·4 ± 85·1 ng/mL RESMENA, both p < 0·001), but no differences were found between either nutritional patterns (table 1) or between genders.
Association between irisin and lipid profile
In the whole sample, a positive relationship was found between the percentage of depletion of irisin levels and the percentage of body weight reduction as compared to baseline values, resulting in a trend towards significance (r = 0·165, p = 0·069).
Moreover, significant associations between the reduction in irisin levels and a depletion in TC (r = 0·269, p = 0·014), TC/HDL-c (r = 0·241, p = 0.029), LDL-c (r= 0·239, p = 0·031) and Apo B (r = 0·345, p = 0·002) were observed. However, changes in total lean mass, SBP, DBP, HDL-c, TG, FFA, glucose or activity level did not show a significant correlation with the irisin variation (table 2) .
Linear regression analyses, adjusted for body weight variation, were applied to evaluate the relationship between changes in plasma irisin levels (ng/mL) and lipid profile biomarker variation (mg/dL), independently of changes in body weight. Among these, changes in TC (B = 0·106, CI95%: 0·019 to 0·193, p = 0·018, r 2 = 0·105), TC/HDL-c ratio (B= 0·002, CI95%: 0·001 to 0·004, p = 0·036, r 2 = -0·100), LDL-c (B= 0·085, CI95%: 0·005 to 0·165, p = 0·037, r 2 = 0·050) and Apo B (B = 0·052, CI95%: 0·020 to 0·084, p = 0·002, r 2 = 0·107) were statistically related to plasma irisin variations ( figure   2 ). However, for HDL-c (p = 0·978), TG (p = 0·204) or FFA (p = 0·364) this association was not statistically significant.
Discussion
The recently discovered myokine, irisin, has received much attention due to the fact that it has been involved in the regulation of human energy metabolism 23, 24 . In the present study it was found that the variation in atherogenic parameters paralleled the changes in irisin levels after weight loss therapy. Therefore, these results suggest that irisin could also be involved in fat metabolism homeostasis or lipid disorders.
As has been found in other studies concerning hypocaloric diets 25 , both control and RESMENA dietary strategies proved to be effective in improving MetS abnormalities.
This conclusion is based on the fact that the general anthropometric and biochemical parameters of the volunteers that are related to MetS were lowered.
Interestingly, irisin levels decreased in both dietary groups after the 2-month-long hypocaloric intervention. Relevant investigations have reported that irisin levels are elevated under obesity and on MetS patients or reduced under anorexia or after weight loss 26, 27 . In order to elucidate if the causes of the observed irisin depletion were in line with the aforementioned investigations, the association between this hormone's variation and changes in body weight, was evaluated. It is worth noting that, a trend towards significance was found in the relationship between the percentage change of irisin levels and the percentage variation of body weight.
The main objective of the current analysis was to evaluate the potential relationships between changes in atherogenic parameters and the variation in irisin levels after a weight loss programme. However, irisin changes can also be related to lean mass and/or exercise level, since it is considered a myokine 2, , 5 28 . A positive correlation between irisin and blood pressure has also been observed 27, 29 . Moreover, it has previously been described that plasma glucose could influence serum irisin levels 30 . Therefore, in order to exclude possible confounding variables, correlation analyses were performed between changes in plasma irisin levels and changes in total lean mass, blood pressure, glucose concentrations or activity level. Nevertheless, no significant relationships were found in this experimental trial.
After finding irisin depletion in the MetS population at the end of the weight loss programme, the analysis of potential relationships of this myokine with the changes in the lipid profile was aimed. Associations between this myokine levels and plasma cholesterol have been previously described in other studies, but there is no general agreement among investigations concerning obese subjects. While Liu et al. 29 showed a positive correlation between this myokine and TC, Huh et al. 31 reported a negative association and Wen et al. 32 observed a positive correlation between irisin and HDL-c, but not with TC or LDL-c. Furthermore, to our knowledge, this is the first report that shows a relationship between irisin and the atherogenic index TC/HDL-c or Apo B levels. Additionally, it should be mentioned that all the above cited studies were crosssectional studies, while our findings belong to a weight-loss intervention trial where an association between irisin changes and TC, LDL-c, TC/HDL-c and Apo B variations is reported.
Although the exact mechanisms of irisin action remain unclear, these findings suggest that irisin may participate in the regulation of lipid metabolism. We speculated that given irisin's putative role as a "metabolism-activator", changes in irisin concentration might reflect a response to metabolic (or atherogenic) burdens. This outcome might therefore explain our observation of a positive correlation between irisin and atherogenic factors such as total cholesterol and Apo B. Moreover, a resistance phenomenon could not be excluded. Indeed, irisin could follow a similar pattern as leptin or insulin, which are elevated in obese subjects and reduced after subjects undergo a hypocaloric diet 33 , as other authors have also suggested 27, 34 .
In addition to the limitations of a post-hoc analysis, it should be mentioned that due to the relatively small sample size, type 2 errors cannot be excluded. Moreover, the investigation was performed on patients suffering MetS following an energy restricted diet; therefore, further studies should be carried out in order to determine whether irisin changes are related to lipid profile in other populations.
In summary, this study shows a positive relationship between the decrease in irisin levels and reductions in plasma lipid profile markers in MetS patients following an energy restricted programme. Further investigations into this myokine might be a good target to better understand not only energy expenditure, as was initially proposed 1,2 , but also the atherogenic dyslipidemia process, which is one of the main concerns of the MetS and obesity conditions.
